Investigating comorbidities and rheumatoid arthritis
Interview and article by Christine Clark. Rheumatoid arthritis (RA) affects about one percent of the population in the UK and comorbidities are reported to be common. A recent… read more.
Interview and article by Christine Clark. Rheumatoid arthritis (RA) affects about one percent of the population in the UK and comorbidities are reported to be common. A recent… read more.
Article written by Bruce Sylvester Researchers report that methotrexate is an effective treatment for people with knee osteoarthritis (OA) who have pain and inflammation.
Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.
A study by O’Leary and colleagues, which appears in Arthritis Care & Research, looks at sedentary behaviour in people with RA and factors that may be associated with it.
In a study by Rebecca Rothwell and colleagues, which appears in Arthritis & Rheumatology, possible considerations of non-inferiority (NI) trials assessing treatment effects in RA are discussed.
Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their… read more.
UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of Cimzia (certolizumab pegol) in the United States, specifically… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced its decision to discontinue the Phase III LOTUS study of Stelara (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to… read more.
The FDA approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA)… read more.
Novartis, announced that the FDA has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), confirming Cosentyx efficacy in addressing the axial spondyloarthritis (axSpA) disease… read more.
AbbVie announced new long-term results showing that once-daily Rinvoq (upadacitinib) continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the… read more.
Gilead Sciences, Inc. and Galapagos NV announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.